AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21615492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 2
Study 19274410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperflex (Cooper Vision)
Number of subjects: 130
Study 19274410 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency(R) 55 Aspheric (Cooper Vision)
Number of subjects: 130
Study 19274410 — intervention group
Group type: EXPERIMENTAL
Intervention: World Vision FW (World Vision)
Number of subjects: 130
Study 19274410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure Vision (Bausch & Lomb)
Number of subjects: 130
Study 19274410 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus Monthly (Ciba Vision)
Number of subjects: 130
Study 19274410 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus Choice AB (Ciba Vision)
Number of subjects: 130
Study 17146319 — intervention group
Group type: EXPERIMENTAL
Intervention: IV rehydration
Number of subjects: 8
Study 17146319 — intervention group
Group type: EXPERIMENTAL
Intervention: ORAL rehydration
Number of subjects: 8
Study 12700305 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Touch (LT; <1 N)
Number of subjects: 18
Study 12700305 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy Touch (HT)
Number of subjects: 18
Study 12700305 — intervention group
Group type: COMPARATOR
Intervention: No Fingertip Touch (NT)
Number of subjects: 18
Study 10924977 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally fractionated (cf) treatment: 60 Gy over 6 weeks (n = 79)
Number of subjects: 152
Study 10924977 — intervention group
Group type: COMPARATOR
Intervention: Palliative accelerated irradiation regimen (PAIR): 32 Gy, 2 Gy b.i.d. (n = 73)
Number of subjects: 152
Study 10924977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 152
Study 8738054 — intervention group
Group type: EXPERIMENTAL
Intervention: alfuzosin
Number of subjects: 260
Study 8738054 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 260
Study 8738054 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 260
Study 1405361 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hypertension to blood pressure values within the normal range
Number of subjects: 0
Study 1405361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diets with ketoacid supplement
Number of subjects: 0
Study 1405361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment of hyperlipidemia
Number of subjects: 0
Study 3902908 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine antiseptic
Number of subjects: 0
Study 3902908 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 3902908 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 0
Study 31197986 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 conjugate vaccine
Number of subjects: 64
Study 31197986 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-DT conjugate vaccine
Number of subjects: 64
Study 29100777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial tubercle lateralization with TT-TG distance of 20 mm
Number of subjects: 9
Study 29100777 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella alta with Caton-Deschamps Index (CDI) of 1.2
Number of subjects: 9
Study 29100777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tibial tubercle lateralization and patella alta
Number of subjects: 9
Study 27358434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose edoxaban regimen (HDER) 60 mg daily or 30 mg daily for CrCl 30-50 mL/min
Number of subjects: 14071
Study 27358434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose edoxaban regimen (HDER)
Number of subjects: 14071
Study 27358434 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14071
Study 24516103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg
Number of subjects: 12
Study 24516103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24516103 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 12
Study 24516103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin with Enalaprilat
Number of subjects: 12
Study 21679921 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 211
Study 21679921 — intervention group
Group type: COMPARATOR
Intervention: Emergency portacaval shunt
Number of subjects: 211
Study 20438400 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.033 mg/kg/day
Number of subjects: 79
Study 20438400 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.067 mg/kg/day
Number of subjects: 79
Study 17063357 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype device for maintaining constant endotracheal cuff pressure (Pcuff)
Number of subjects: 9
Study 17063357 — intervention group
Group type: COMPARATOR
Intervention: Control day with manometer monitoring and adjusting Pcuff
Number of subjects: 9
Study 16283123 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized diagnostic assessment including self-reporting, clinical interview, and laboratory measures.
Number of subjects: 55118
Study 16283123 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive standardized laboratory screening program and 12-month follow-up investigation.
Number of subjects: 55118
Study 11838724 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert group (viewed 4 translated educational videotapes about pain management)
Number of subjects: 46
Study 11838724 — intervention group
Group type: COMPARATOR
Intervention: Nonexpert group (received no pain education)
Number of subjects: 46
Study 11838724 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert group
Number of subjects: 46
Study 11838724 — intervention group
Group type: COMPARATOR
Intervention: Nonexpert group
Number of subjects: 46
Study 11838724 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire sample (n = 30)
Number of subjects: 46
Study 12016800 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5‐7.5 mg.d‐1)
Number of subjects: 8
Study 12016800 — intervention group
Group type: COMPARATOR
Intervention: Dihydro-chlorothiazide (50‐70 mg.d‐1)
Number of subjects: 8
Study 12016800 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (150‐300 mg.d‐1)
Number of subjects: 8
Study 8824659 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated phosphatidyl choline (900 mg orally daily)
Number of subjects: 22
Study 8824659 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study 1614464 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard immune globulin (400 mg per kilogram of body weight)
Number of subjects: 352
Study 1614464 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-lipopolysaccharide hyperimmune globulin (400 mg per kilogram)
Number of subjects: 352
Study 1614464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (25 percent albumin, 8 ml per kilogram)
Number of subjects: 352
Study 6584446 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 0
Study 6584446 — intervention group
Group type: EXPERIMENTAL
Intervention: CuSO4
Number of subjects: 0
Study 6584446 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 0
Study 30507280 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise (treadmill walking)
Number of subjects: 51
Study 30507280 — intervention group
Group type: COMPARATOR
Intervention: No structured exercise
Number of subjects: 51
Study 29288775 — intervention group
Group type: EXPERIMENTAL
Intervention: polihexanide 0.04%
Number of subjects: 61
Study 29288775 — intervention group
Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 61
Study 26852095 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) combined with maintenance antidepressant medication (mADM)
Number of subjects: 317
Study 26852095 — intervention group
Group type: COMPARATOR
Intervention: Maintenance antidepressant medication (mADM)
Number of subjects: 317
Study 25315287 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimising TB/HIV service integration intervention
Number of subjects: 0
Study 25315287 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 22386385 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative duplex vein mapping (DVM)
Number of subjects: 130
Study 22386385 — intervention group
Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 130
Study 19671565 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection Troynoxa (enoxaparin sodium 40 mg/0.4 mL)
Number of subjects: 12
Study 19671565 — intervention group
Group type: COMPARATOR
Intervention: Injection Clexane (enoxaparin sodium 40 mg/0.4 mL)
Number of subjects: 12
Study 17267793 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine
Number of subjects: 320
Study 17267793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 15958318 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30
Study 15958318 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study 12190161 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg <70 kg b.w. or 3 mg >70 kg b.w.) and propofol (median dose 80 mg, range 40-150)
Number of subjects: 120
Study 12190161 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (median dose 5 mg, range 3-7) and pethidine (75 mg, range 50-125)
Number of subjects: 120
Study 12190161 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and propofol
Number of subjects: 120
Study 9973029 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with heparin (5,000 U bolus, 1,000 to 1,300 U/h infusion)
Number of subjects: 3759
Study 9973029 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with hirudin (0.1 to 0.6 mg/kg bolus, 0.1 to 0.2 mg/kg/h infusion)
Number of subjects: 3759
Study 9973029 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >70 years
Number of subjects: 3759
Study 9973029 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 3759
Study 9973029 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior angina
Number of subjects: 3759
Study 9973029 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >70 years (nonrupture death)
Number of subjects: 3759
Study 9973029 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior MI (nonrupture death)
Number of subjects: 3759
Study 9973029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of anticoagulation (heparin or hirudin)
Number of subjects: 3759
Study 7762773 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (constant minute ventilation)
Number of subjects: 44
Study 7762773 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (minute ventilation increased to keep paCO2 constant)
Number of subjects: 44
Study 1967767 — intervention group
Group type: EXPERIMENTAL
Intervention: B9AspB27Glu
Number of subjects: 6
Study 1967767 — intervention group
Group type: COMPARATOR
Intervention: Actrapid HM U100
Number of subjects: 6
Study 7064876 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal rich in phosphatidylcholine
Number of subjects: 6
Study 7064876 — intervention group
Group type: COMPARATOR
Intervention: Control meal low in phosphatidylcholine
Number of subjects: 6
Study 30758076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% rhFGF-2 + DBBM (test)
Number of subjects: 44
Study 30758076 — intervention group
Group type: COMPARATOR
Intervention: rhFGF-2 alone (control)
Number of subjects: 44
Study 30758076 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 28168555 — intervention group
Group type: EXPERIMENTAL
Intervention: HImax (80% 1RM)
Number of subjects: 36
Study 28168555 — intervention group
Group type: EXPERIMENTAL
Intervention: LOmax (40% 1RM preceded by 60 repetitions at 20-25% 1RM)
Number of subjects: 36
Study 28168555 — intervention group
Group type: EXPERIMENTAL
Intervention: LO (40% 1RM)
Number of subjects: 36
Study 28168555 — intervention group
Group type: COMPARATOR
Intervention: Overall (all groups)
Number of subjects: 36
Study 28168555 — intervention group
Group type: COMPARATOR
Intervention: sTNFR1 and IL-1RA
Number of subjects: 36
Study 28168555 — intervention group
Group type: COMPARATOR
Intervention: IL-1beta, IL-10, GM-CSF
Number of subjects: 36
Study 26709238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch 10 mg/16 hr for 8 weeks
Number of subjects: 291
Study 26709238 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 291
Study 26709238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch 15 mg/16 hr for 8 weeks
Number of subjects: 291
Study 26709238 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline for 12 weeks
Number of subjects: 291
Study 24157951 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqualase
Number of subjects: 100
Study 24157951 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 100
Study 22654429 — intervention group
Group type: COMPARATOR
Intervention: 7-day conventional triple therapy
Number of subjects: 460
Study 22654429 — intervention group
Group type: COMPARATOR
Intervention: 10-day conventional triple therapy
Number of subjects: 460
Study 22654429 — intervention group
Group type: COMPARATOR
Intervention: 14-day conventional triple therapy
Number of subjects: 460
Study 22654429 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy
Number of subjects: 460
Study 19464125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (HYD) 12 mg IM
Number of subjects: 13
Study 19464125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (HYD) 24 mg IM
Number of subjects: 13
Study 19464125 — intervention group
Group type: COMPARATOR
Intervention: Money reinforcement ($2 or $4)
Number of subjects: 13
Study 17364587 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of olmesartan (20 mg)
Number of subjects: 18
Study 17364587 — intervention group
Group type: COMPARATOR
Intervention: Evening dosing of olmesartan (20 mg)
Number of subjects: 18
Study 15164513 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antianginal drugs and membran‐oprotective drugs (MPD)
Number of subjects: 59
Study 15164513 — intervention group
Group type: COMPARATOR
Intervention: Antianginal drugs alone
Number of subjects: 59
Study 11136274 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen (500-1000 mg/day) and misoprostol (200 microg b.d.)
Number of subjects: 90
Study 11136274 — intervention group
Group type: COMPARATOR
Intervention: nabumetone (1000-1500 mg/day) and placebo misoprostol
Number of subjects: 90
Study 9589757 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment (ACT)
Number of subjects: 0
Study 9589757 — intervention group
Group type: COMPARATOR
Intervention: Standard case management (SCM)
Number of subjects: 0
Study 8045844 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day)
Number of subjects: 11
Study 8045844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8045844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11
Study 2927553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase with 5 X 10(5) IU (SK‐i.v.) in group A before transport
Number of subjects: 76
Study 2927553 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase with 5 X 10(5) IU (SK‐i.v.) in group B after transport
Number of subjects: 76
Study 30894394 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-injection training for DMPA-SC
Number of subjects: 731
Study 30894394 — intervention group
Group type: COMPARATOR
Intervention: Provider-administered DMPA-SC
Number of subjects: 731
Study 28219801 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) - 10 cycles, using DIOMED Light or PhotoDYN Light
Number of subjects: 100
Study 25189167 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 35
Study 25189167 — intervention group
Group type: EXPERIMENTAL
Intervention: β-hydroxybutyrate
Number of subjects: 35
Study 25189167 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 35
Study 25189167 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 35
Study 23312939 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles at 60 bpm
Number of subjects: 15
Study 23312939 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles at 75 bpm
Number of subjects: 15
Study 23312939 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles at 86 bpm
Number of subjects: 15
Study 23312939 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles at 100 bpm
Number of subjects: 15
Study 23312939 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles
Number of subjects: 15
Study 23312939 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements before stimulation
Number of subjects: 15
Study 21681863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (TAPS)
Number of subjects: 40
Study 21681863 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 40
Study 19332194 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy post-fibrinolysis (n = 1,583)
Number of subjects: 3153
Study 19332194 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy post-fibrinolysis (n = 1,570)
Number of subjects: 3153
Study 19332194 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5 (highest TRI risk)
Number of subjects: 3153
Study 19332194 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4
Number of subjects: 3153
Study 19332194 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3
Number of subjects: 3153
Study 19332194 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3153
Study 16378915 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea capsules
Number of subjects: 34
Study 16378915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12946074 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-coated ceramic surface with Panavia 21 and silane/bonding agent
Number of subjects: 100
Study 12946074 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-coated ceramic surface with Panavia 21 without silanization
Number of subjects: 100
Study 12946074 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated ceramic surface with Panavia 21 and silane/bonding agent
Number of subjects: 100
Study 12946074 — intervention group
Group type: COMPARATOR
Intervention: Untreated ceramic surface with Panavia 21 without silanization (control)
Number of subjects: 100
Study 12946074 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-coated ceramic surface with RelyX ARC
Number of subjects: 100
Study 12946074 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated ceramic surface with RelyX ARC
Number of subjects: 100
Study 11776174 — intervention group
Group type: EXPERIMENTAL
Intervention: One antibiotic given for three days (group B)
Number of subjects: 45
Study 11776174 — intervention group
Group type: EXPERIMENTAL
Intervention: Only once antibiotic used (group C)
Number of subjects: 45
Study 11776174 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic given (group A)
Number of subjects: 45
Study 11776174 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 45
Study 11776174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cesarean section and antibiotics
Number of subjects: 45
Study 9049798 — intervention group
Group type: COMPARATOR
Intervention: Free gingival grafts (Group A)
Number of subjects: 70
Study 9049798 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpedicle grafts (Group B)
Number of subjects: 70
Study 8383058 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg x 2
Number of subjects: 60
Study 8383058 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg x 2 (in reference group)
Number of subjects: 60
Study 8383058 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg x 2
Number of subjects: 60
Study 8383058 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg x 3
Number of subjects: 60
Study 8383058 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo x 2
Number of subjects: 60
Study 3087862 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (5 X 10(6) IU) administered once daily subcutaneously during a five day treatment period followed by a three month maintenance period (1 X 10(6) IU three times weekly)
Number of subjects: 31
Study 31795756 — intervention group
Group type: EXPERIMENTAL
Intervention: JNFS loaded with buffered 1% lidocaine
Number of subjects: 28
Study 31795756 — intervention group
Group type: COMPARATOR
Intervention: JNFS loaded with sterile normal saline (Control)
Number of subjects: 28
Study 29109117 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac and erlotinib
Number of subjects: 20
Study 29109117 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 27616435 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (XCM)
Number of subjects: 20
Study 27616435 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated site)
Number of subjects: 20
Study 25574960 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 2895
Study 25574960 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 2895
Study 25574960 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 2895
Study 25574960 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight at ART initiation
Number of subjects: 2895
Study 25574960 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at ART initiation
Number of subjects: 2895
Study 25574960 — intervention group
Group type: COMPARATOR
Intervention: Sex
Number of subjects: 2895
Study 25574960 — intervention group
Group type: COMPARATOR
Intervention: CD4(+) cell count
Number of subjects: 2895
Study 25574960 — intervention group
Group type: COMPARATOR
Intervention: CD4(+) cell count monitoring
Number of subjects: 2895